Experts are rapidly investigating retatrutide, a promising drug developed by Eli Lilly, as a significant step in body management. Unlike many previous approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, hormones that impact satiety and glucose control . Early research t